Redwood City, CA, United States of America

Ash Jogalekar

This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Revolution Medicines, Inc.. Active years: 2023-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ash Jogalekar. Retrieved from https://idiyas.com/inventor/ash-jogalekar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 2 

% Patents Active = 100.0


Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ash Jogalekar: Innovator in Pharmaceutical Chemistry

Introduction

Ash Jogalekar is a notable inventor based in Redwood City, CA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds that target specific biological pathways.

Latest Patents

Ash Jogalekar holds 2 patents. His latest patents include "Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors." This patent focuses on inhibitors of SHP2, which are crucial in the treatment of diseases associated with this protein. The disclosure details compounds of Formula IV as inhibitors of SHP2 and their potential use in pharmaceutical compositions.

Career Highlights

Ash is currently employed at Revolution Medicines, Inc., where he continues to advance his research in drug development. His work is instrumental in creating innovative solutions for complex medical challenges.

Collaborations

Some of his notable coworkers include Brian R Blank and Jennifer Pitzen, who contribute to the collaborative environment at Revolution Medicines, Inc.

Conclusion

Ash Jogalekar's work exemplifies the impact of innovative research in the pharmaceutical industry. His patents and ongoing contributions are paving the way for new therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…